CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($)	3 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Cash flows from operating activities
Net loss	$ (491,837)	$ (6,625,833)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation expense	4,251	4,251
Gain (loss) on debt extinguishment	(2,434,661)	2,268,373
Decrease (increase) in fair value of derivative liabilities	2,795	(6,886)
Amortization of discount on notes payable	759,869	882,440
Accrued interest on patent purchase	52,067	0
Amortization of patents and acquired contracts	405,995	415,834
Stock-based compensation	130,358	472,274
Changes in operating assets and liabilities
Accounts receivable	(6,281)	248,501
Inventories	0	130,155
Prepaid expenses and other current assets	133,931	(33,181)
Deferred expenses	20,875	(96,305)
Accounts payable	(95,287)	663,097
Accrued expenses and other current liabilities	172,238	208,014
Deferred revenue	150,000	446,429
Net cash used in operating activities	(1,195,687)	(1,022,837)
Cash flows from financing activities
Proceeds from issuance of preferred stock, net of issuance costs	2,175,000	0
Proceeds from issuance of notes payable, net of issuance costs	0	1,126,900
Payments on short-term notes payable, related party	(25,000)	0
Payments on Fortress notes payable	(658,757)	0
Net cash provided by financing activities	1,491,243	1,126,900
Net increase in cash and cash equivalents	295,556	104,063
Cash and cash equivalents, beginning of period	554,556	1,443,349
Cash and cash equivalents, end of period	850,112	1,547,412
Supplemental disclosures of cash flow information
Cash paid for interest	218,139	146,042
Cash paid for income taxes	0	0
Supplemental disclosures of non-cash investing and financing activities
Accrued guaranteed payments and deferred expenses associated with purchased patent assets	0	440,783
Fair value of common stock warrants	$ 760,461	$ 0